Drug Trial Radar · NCT04102696
ARomatherapy for Cognitive Trajectory in Chinese After Coronary Artery Bypass Grafting
Last checked: Nov 20, 2026Latest source record: Sep 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
460
Planned (sponsor's estimate)
Start
Dec 2019
Primary completion
Dec 2020
Study completion Jun 2021
Sponsor
- Lead sponsor
- Beijing Anzhen HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking University
- First posted
- Sep 25, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ARCTIC-CABG (Aromatherapy for Cognitive Trajectory in Chinese after Coronary Artery Bypass Grafting) trial is a randomized, double-blind, 2-arm, parallel group, placebo-controlled study to evaluated the effects of Aromatherapy in improving cognitive function in post-Coronary Artery Bypass Grafting (CABG) patients. The study will recruit 460 patients who undergo a first-time CABG at the Department of Cardiac Surgery in Beijing Anzhen Hospital. Baseline information will be collected prior to CABG, all eligible participants undergoing CABG will be randomly assigned in a 1:1 ratio before hospital discharge to receive aromatherapy (70% menthol and 30% propanediol) or placebo (10% menthol and 90% propanediol). The treatment will last for 6 months in both groups. Cognitive function measurement will be conducted by blinded assessors at baseline (1-3 days before CABG) and at 3- and 6-month after CABG. The primary outcome will be the change in overall cognitive function (MOCA score) from baseline to 6-month after CABG.
Conditions
- Coronary Artery Bypass Grafting
- Myocardial Infarction
Interventions
AromatherapyDrug
Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge. The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal.
PlaceboDrug
Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in the overall cognitive function at 6 months after CABGTime frame: before and after 6-month intervention
- Changes in the overall cognitive function at 3 months after CABGTime frame: before and after 6-month intervention
- Changes in the memory function at 3- and 6- month after CABGTime frame: before and after 3- and 6-month intervention
- Changes in the executive function: semantic fluency, at 3- and 6- month after CABGTime frame: before and after 3- and 6-month intervention
- Changes in the executive function: visual attention, at 3- and 6- month after CABGTime frame: before and after 3- and 6-month intervention
- Changes in the orientation function at 3- and 6- month after CABGTime frame: before and after 3- and 6-month intervention
- The proportion of patients with mild cognitive impairment at 3- and 6- month after CABGTime frame: before and after 3- and 6- month intervention
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.